Bicyclic Peptides As Type I/Type Ii Beta-Turn Scaffolds(399 views visite) Lombardi A, D'Auria G, Saviano M, Maglio O, Nastri F, Quartara L, Pedone C, Pavone V
Keywords Parole chiave: β-Turn, Molecular Scaffolds, Tachykinin Antagonist, X-Ray, Characterization, Composition, Molecular Structure, Nuclear Magnetic Resonance Spectroscopy, Synthesis (chemical), X Rays, Bicyclic Peptides, Neurokinin, Amino Acids, Neurokinin 2 Receptor Antagonist, Amino Acid Sequence, Article, Molecular Interaction, Protein Conformation, Protein Structure, Crystallography, Hydrogen Bonding, Models, Secondary,
Affiliations Affiliazioni: CIRPB, CEINGE-Biotecnologie Avanzate, Ctro. Studio Biocristallografia-CNR, Via Mezzocannone 4, I-80134 Napoli, Italy
References Riferimenti: Not available. Non disponibili.
Bicyclic Peptides As Type I/Type Ii Beta-Turn Scaffolds
We recently reported the rational design, synthesis, and structural characterization of the most potent and selective peptide-based neurokinin A antagonist thus far described: cyclo (Met (1) -Asp (2) -Trp (3) -Phe (4) -Dap (5) -Leu (6)) cyclo (2 beta-5 beta). Its bicyclic structure is characterized by a type I and a type II two beta-turn around Trp (3) -Phe (4) and Leu (6) -Met (1), respectively. In order to understand whether the two different beta-turned structures are determined by the bicyclic structure or by the amino acid type at the corner positions, we have synthesized the pseudo-symmetrical analogue cyclo (Phe (1) -Asp (2) -Trp (3) -Phe (4) -Dap (5) -Trp (6)) cyclo (2 beta-5 beta). The structural characterization in the crystal state and in solution, here reported, gives an experimental evidence that the backbone of the bicyclic structure is a rigid scaffold that can be used to build both a type I and type II beta-turn independently from the amino acid composition. (C) 1997 John Wiley & Sons, Inc
Bicyclic Peptides As Type I/Type Ii Beta-Turn Scaffolds
Malvindi MA, Greco A, Conversano F, Figuerola A, Corti M, Bonora M, Lascialfari A, Doumari HA, Moscardini M, Cingolani R, Gigli G, Casciaro S, Pellegrino T, Ragusa A * MR Contrast Agents(230 visite) Small Animal Imaging, 2011 Jul 8; 21(13): 2548-2555. Impact Factor:1.784 DettagliEsporta in BibTeXEsporta in EndNote
417 Records (396 escludendo Abstract e Conferenze). Impact factor totale: 1490 (1435.115 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 1565.292 (1481.485 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:15:15 399 views visite. Last view on Ultima visita in data Thursday 25 February 2021, 16:48:35